



Send a release
Member sign in ▾
Become a member
For journalists
Global sites ▾

Search

Advanced Search

Products & Services

News Releases



Products & Services ▾

Knowledge Center

Browse News Releases

Contact PR Newswire ▾

See more news releases in: [Health Care & Hospitals](#), [Medical Pharmaceuticals](#), [Economic News, Trends, Analysis](#)

Diabetes Diagnosis, Treatment and Drug Delivery Market will Almost Triple in Value by 2016, Says iData Research

Continuous Glucose Monitoring Systems Market to Grow 48% in 2009

VANCOUVER, Oct. 6 /PRNewswire/ - According to a new report series by iData Research, the leading global authority in medical device, dental and pharmaceutical market research, the U.S. market for diabetes drugs, devices and monitoring systems will reach over \$55 billion by 2016, tripling in value. The market for insulin will grow over 18% in 2009, while continuous glucose monitoring systems will see growth of 48%. iData's new report provides comprehensive analysis of the blood glucose monitoring, insulin delivery and antidiabetic drug markets.

The report states that of the 28 million diabetics in the U.S. in 2009, almost 24% were undiagnosed. This is expected to change as more insurance companies offer reimbursement for diabetic screening.

"The diabetes diagnosis and blood glucose monitoring markets are seeing rapid growth as more Type 2 diabetes patients are diagnosed each year," says Dr. Kamran Zamanian, CEO of iData. "Revenues in the insulin and oral antidiabetic drug markets are increasing at rates approximately double the rate of growth of the diagnosed diabetic population."

iData's report covers diabetes devices including traditional blood glucose monitoring meters, continuous monitoring systems, test strips, lancets and lancing devices, insulin syringes, insulin pens and insulin pumps. Insulin pens are becoming more widely used at the expense of syringes, with the insulin pen market growing by over 17% in 2009, as the preferences of patients shift. Within the diabetic devices market, companies such as Abbott, Bayer, Eli Lilly, Lifescan, Medtronic and Roche lead the market.

The report also covers the insulin market as well as oral and injectable antidiabetic drugs. Oral drugs are estimated to see double-digit growth through 2016, with companies such as Amylin, Bristol-Myers, Squibb, GlaxoSmithKline, Merck & Co., Novo Nordisk, Pfizer and Takeda leading the market.

More information can be found by registering free on their website at: <http://www.idataresearch.net/idata/registration.php>

About iData Research

iData Research (www.idataresearch.net) is an international market research and consulting group focused on providing market intelligence for medical device, dental and pharmaceutical companies. iData covers research in: Diabetes Drugs, Diabetes Devices, Pharmaceuticals, Anesthesiology, Wound Management, Orthopedics, Cardiovascular, Dental, Endoscopy, Gynecology and more.

View iData's 3-minute Movie: www.idataresearch.net/discoveridata.html

SOURCE iData Research Inc.

RSS Feeds

Print

Email

Share it ▾

Blog it ▾

Blog Search ▾

Other News Releases in Health Care & Hospitals

\$100,000 Allstate Foundation Grant SCORES Help for Texas DV Survivors

BD Announces FDA 510(k) Clearance of BD Vacutainer(R) Rapid Serum Blood Collection Tube

Mobile Industry Extends Reach of Healthcare Programs in Emerging Markets

Other News Releases in Economic News, Trends, Analysis

Clarksville, Tenn. Leading in Recession Recovery

Alliance for Digital Equality(TM) Chairman Participates in FCC Hearing on Broadband Adoption in Charleston, South Carolina

Ethnic Americans Support Federal Stimulus Spending; Most Americans Question Current Impact of Package

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.